Free Trial

HEALTHCARE: Glaxo (GSK: A2/A): Blenrep - Good News

HEALTHCARE

Not a spread mover but keeps the ball rolling

  • Blenrep is GSK's competitor to Darzalex in the Myeloma space
  • JNJ sells $11.6bn of Darzalex annually
  • Peak sales of Blenrep are expected to be over $3bn according to GSK's CCO
  • Blenrep has just had its 6th "major regulatory filing acceptance this year"
  • US decision expected by 23 July 2025

    Media Link
54 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Not a spread mover but keeps the ball rolling

  • Blenrep is GSK's competitor to Darzalex in the Myeloma space
  • JNJ sells $11.6bn of Darzalex annually
  • Peak sales of Blenrep are expected to be over $3bn according to GSK's CCO
  • Blenrep has just had its 6th "major regulatory filing acceptance this year"
  • US decision expected by 23 July 2025

    Media Link